(Q37785528)

23 August 2017

title

Population pharmacokinetics of therapeutic monoclonal antibodies (English)

1 reference

23 August 2017

1 reference

1 reference

1 reference

Nathanael L Dirks

1

1 reference

23 August 2017

Bernd Meibohm

series ordinal

2

1 reference

23 August 2017

publication date

1 October 2010

1 reference

Clinical Pharmacokinetics

23 August 2017

published in

1 reference

23 August 2017

volume

49

1 reference

23 August 2017

issue

10

1 reference

23 August 2017

page(s)

633-659

1 reference

https://scigraph.springernature.com/pub.10.2165/11535960-000000000-00000

23 August 2017

exact match

0 references

cites work

Denosumab: an investigational drug for the management of postmenopausal osteoporosis

1 reference

12 December 2020

Monoclonal antibodies as innovative therapeutics

1 reference

12 December 2020

Infliximab pharmacokinetics in inflammatory bowel disease patients.

1 reference

12 December 2020

Panitumumab the first fully human monoclonal antibody: from the bench to the clinic

1 reference

12 December 2020

Identifiability and indistinguishability of nonlinear pharmacokinetic models

1 reference

12 December 2020

Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene

1 reference

12 December 2020

1 reference

12 December 2020

Evidence to support the cellular mechanism involved in serum IgG homeostasis in humans

1 reference

12 December 2020

A population pharmacokinetic-pharmacodynamic analysis of single doses of clenoliximab in patients with rheumatoid arthritis

1 reference

12 December 2020

ING-1, a monoclonal antibody targeting Ep-CAM in patients with advanced adenocarcinomas

1 reference

12 December 2020

Elimination mechanisms of therapeutic monoclonal antibodies

1 reference

12 December 2020

Population pharmacokinetics of efalizumab (humanized monoclonal anti-CD11a antibody) following long-term subcutaneous weekly dosing in psoriasis subjects

1 reference

12 December 2020

Population pharmacokinetic studies in pediatrics: issues in design and analysis

1 reference

12 December 2020

Pharmacokinetic and pharmacodynamic considerations in the development of therapeutic proteins

1 reference

12 December 2020

Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial

1 reference

12 December 2020

The transmission of immunity from mother to young and the catabolism of immunoglobulins

1 reference

12 December 2020

Antibody pharmacokinetics and pharmacodynamics

1 reference

12 December 2020

Functional reconstitution of human FcRn in Madin-Darby canine kidney cells requires co-expressed human beta 2-microglobulin

1 reference

12 December 2020

Perspective-- FcRn transports albumin: relevance to immunology and medicine

1 reference

12 December 2020

Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer

1 reference

12 December 2020

Pharmacokinetic drug-drug interaction potentials for therapeutic monoclonal antibodies: reality check

1 reference

12 December 2020

Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment response

1 reference

12 December 2020

Population pharmacokinetics of cetuximab in patients with squamous cell carcinoma of the head and neck.

1 reference

12 December 2020

Finally! The Brambell receptor (FcRB). Mediator of transmission of immunity and protection from catabolism for IgG.

1 reference

12 December 2020

Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin.

1 reference

12 December 2020

Transcytosis: crossing cellular barriers

1 reference

12 December 2020

Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice

1 reference

12 December 2020

Population pharmacokinetic data analysis of three phase I studies of matuzumab, a humanised anti-EGFR monoclonal antibody in clinical cancer development

1 reference

12 December 2020

FcRn: the MHC class I-related receptor that is more than an IgG transporter

1 reference

12 December 2020

Visualizing the site and dynamics of IgG salvage by the MHC class I-related receptor, FcRn.

1 reference

12 December 2020

Population pharmacokinetics and pharmacodynamics of the anti-CD11a antibody hu1124 in human subjects with psoriasis.

1 reference

12 December 2020

Minireview: the OPG/RANKL/RANK system

1 reference

12 December 2020

Population pharmacokinetics I: background, concepts, and models

1 reference

12 December 2020

Clinical pharmacokinetics of bevacizumab in patients with solid tumors.

1 reference

12 December 2020

Safety and pharmacokinetics of an intramuscular monoclonal antibody (SB 209763) against respiratory syncytial virus (RSV) in infants and young children at risk for severe RSV disease

1 reference

12 December 2020

Pharmacologic target-mediated drug disposition

1 reference

12 December 2020

Metabolic properties of IgG subclasses in man

1 reference

12 December 2020

Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

1 reference

12 December 2020

Safety and pharmacokinetics of daclizumab in pediatric renal transplant recipients.

1 reference

12 December 2020

FcRn-mediated transcytosis of immunoglobulin G in human renal proximal tubular epithelial cells

1 reference

12 December 2020

Expression of functionally active FcRn and the differentiated bidirectional transport of IgG in human placental endothelial cells

1 reference

12 December 2020

Population pharmacokinetics of infliximab in patients with ankylosing spondylitis

1 reference

12 December 2020

Population pharmacokinetic analysis of panitumumab in patients with advanced solid tumors

1 reference

12 December 2020

Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease

1 reference

12 December 2020

Exposure-effect population model of inolimomab, a monoclonal antibody administered in first-line treatment for acute graft-versus-host disease

1 reference

12 December 2020

Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis

1 reference

12 December 2020

Pharmacokinetics of cetuximab after administration of escalating single dosing and weekly fixed dosing in patients with solid tumors

1 reference

12 December 2020

Lymphatic absorption is the primary contributor to the systemic availability of epoetin Alfa following subcutaneous administration to sheep.

1 reference

12 December 2020

Molecular, biologic, and pharmacokinetic properties of monoclonal antibodies: impact of these parameters on early clinical development

1 reference

12 December 2020

Metabolism of immunoglobulins

1 reference

12 December 2020

Population pharmacokinetics of sibrotuzumab, a novel therapeutic monoclonal antibody, in cancer patients

1 reference

12 December 2020

Target-mediated drug disposition and dynamics

1 reference

12 December 2020

Integrated cellular bone homeostasis model for denosumab pharmacodynamics in multiple myeloma patients

1 reference

12 December 2020

Pharmacokinetic/pharmacodynamic models for the depletion of Vbeta5.2/5.3 T cells by the monoclonal antibody ATM-027 in patients with multiple sclerosis, as measured by FACS

1 reference

12 December 2020

Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis

1 reference

12 December 2020

Pharmacokinetic/pharmacodynamic studies in drug product development

1 reference

12 December 2020

Intracellular traffic of the MHC class I-like IgG Fc receptor, FcRn, expressed in epithelial MDCK cells

1 reference

12 December 2020

FcRn: the neonatal Fc receptor comes of age.

1 reference

12 December 2020

Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic-pharmacodynamic modeling of biologics

1 reference

12 December 2020

Pharmacokinetic aspects of biotechnology products

1 reference

12 December 2020

Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease.

1 reference

12 December 2020

Monoclonal antibody "gold rush".

1 reference

12 December 2020

Integration of pharmacokinetic and pharmacodynamic studies in the discovery, development, and review of protein therapeutic agents: a conference report

1 reference

12 December 2020

Population pharmacokinetics of antifibroblast activation protein monoclonal antibody F19 in cancer patients

1 reference

12 December 2020

Pharmacokinetic-pharmacodynamic-efficacy analysis of efalizumab in patients with moderate to severe psoriasis.

1 reference

12 December 2020

Population pharmacokinetics of humanized monoclonal antibody HuCC49deltaCH2 and murine antibody CC49 in colorectal cancer patients

1 reference

12 December 2020

A review of the physiological and immunological functions of biliary epithelial cells: targets for primary biliary cirrhosis, primary sclerosing cholangitis and drug-induced ductopenias

1 reference

12 December 2020

Kinetics of FcRn-mediated recycling of IgG and albumin in human: pathophysiology and therapeutic implications using a simplified mechanism-based model

1 reference

12 December 2020

The role of the lymphatic system in subcutaneous absorption of macromolecules in the rat model

1 reference

12 December 2020

Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration

1 reference

12 December 2020

Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.

1 reference

12 December 2020

A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab.

1 reference

12 December 2020

Approximations of the target-mediated drug disposition model and identifiability of model parameters.

1 reference

12 December 2020

Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor

1 reference

12 December 2020

Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies

1 reference

12 December 2020

Bidirectional transcytosis of IgG by the rat neonatal Fc receptor expressed in a rat kidney cell line: a system to study protein transport across epithelia.

1 reference

12 December 2020

Population Pharmacokinetics/Dynamics*

1 reference

12 December 2020

Bidirectional FcRn-dependent IgG transport in a polarized human intestinal epithelial cell line

1 reference

12 December 2020

Basic science for the clinician 47[corrected]: Fcgamma receptors

1 reference

12 December 2020

Disposition and immunodynamics of basiliximab in liver allograft recipients

1 reference

12 December 2020

Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trials

1 reference

12 December 2020

Rationale for fixed dosing of pertuzumab in cancer patients based on population pharmacokinetic analysis

1 reference

12 December 2020

Targeting colorectal cancer with human anti-EGFR monoclonocal antibodies: focus on panitumumab.

1 reference

12 December 2020

Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma

1 reference

12 December 2020

Monoclonal antibody pharmacokinetics and pharmacodynamics

1 reference

12 December 2020

Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasis

1 reference

12 December 2020

A population pharmacokinetic screen to identify demographic-clinical covariates of basiliximab in liver transplantation

1 reference

12 December 2020

Constructing a prediction interval for time to reach a threshold concentration based on a population pharmacokinetic analysis: an application to basiliximab in renal transplantation.

1 reference

12 December 2020

10.2165/11535960-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

23 August 2017

1006906500

0 references

1 reference